These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30284558)

  • 21. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial.
    Nelson SE; Giugliano RP; Antman EM; Park JG; Norden AD; Rost NS; Silverman S; Singhal AB; Lanz HJ; Braunwald E; Ruff CT;
    J Clin Neurosci; 2021 Apr; 86():294-300. PubMed ID: 33446422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation.
    Weitz JI; Eikelboom J
    Thromb Haemost; 2016 Jan; 115(2):257-70. PubMed ID: 26466666
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial.
    Boriani G; Ruff CT; Kuder JF; Shi M; Lanz HJ; Rutman H; Mercuri MF; Antman EM; Braunwald E; Giugliano RP
    Eur Heart J; 2019 May; 40(19):1541-1550. PubMed ID: 30624719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
    De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Reimitz PE; Kirchhof P;
    J Cardiovasc Med (Hagerstown); 2019 Feb; 20(2):97-104. PubMed ID: 30540648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48.
    Zelniker TA; Ruff CT; Wiviott SD; Blanc JJ; Cappato R; Nordio F; Mercuri MF; Lanz H; Antman EM; Braunwald E; Giugliano RP
    Eur Heart J Acute Cardiovasc Care; 2019 Mar; 8(2):176-185. PubMed ID: 30039978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial.
    Wilkinson C; Wu J; Searle SD; Todd O; Hall M; Kunadian V; Clegg A; Rockwood K; Gale CP
    BMC Med; 2020 Dec; 18(1):401. PubMed ID: 33357217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal Function Considerations for Stroke Prevention in Atrial Fibrillation.
    Fanikos J; Burnett AE; Mahan CE; Dobesh PP
    Am J Med; 2017 Sep; 130(9):1015-1023. PubMed ID: 28502818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Edoxaban vs. Warfarin in East Asian Patients With Atrial Fibrillation　- An ENGAGE AF-TIMI 48 Subanalysis.
    Yamashita T; Koretsune Y; Yang Y; Chen SA; Chung N; Shimada YJ; Kimura T; Miyazaki K; Abe K; Mercuri M; Ruff CT; Giugliano RP
    Circ J; 2016; 80(4):860-9. PubMed ID: 26888149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding.
    Hospodar AR; Smith KJ; Zhang Y; Hernandez I
    Am J Cardiovasc Drugs; 2018 Aug; 18(4):317-325. PubMed ID: 29740750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF - TIMI 48 Trial: Taiwanese Perspective.
    Vilain KA; Yang MC; Hui Tan EC; Wang K; Li H; Hsu WH; Giugliano RP; Cohen DJ; Magnuson EA;
    Value Health Reg Issues; 2017 May; 12():74-83. PubMed ID: 28648320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
    Giugliano RP; Ruff CT; Rost NS; Silverman S; Wiviott SD; Lowe C; Deenadayalu N; Murphy SA; Grip LT; Betcher JM; Duggal A; Dave J; Shi M; Mercuri M; Antman EM; Braunwald E;
    Stroke; 2014 Aug; 45(8):2372-8. PubMed ID: 24947287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).
    De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Kerschnitzki M; Reimitz PE; Kirchhof P;
    BMC Cardiovasc Disord; 2019 Jul; 19(1):165. PubMed ID: 31299906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Edoxaban: a review in nonvalvular atrial fibrillation.
    McCormack PL
    Am J Cardiovasc Drugs; 2015 Oct; 15(5):351-61. PubMed ID: 26369340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.
    Magnani G; Giugliano RP; Ruff CT; Murphy SA; Nordio F; Metra M; Moccetti T; Mitrovic V; Shi M; Mercuri M; Antman EM; Braunwald E
    Eur J Heart Fail; 2016 Sep; 18(9):1153-61. PubMed ID: 27349698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anticoagulation Control in Warfarin-Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin-Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation Trial).
    Lip GYH; Al-Saady N; Jin J; Sun M; Melino M; Winters SM; Zamoryakhin D; Goette A
    Am J Cardiol; 2017 Sep; 120(5):792-796. PubMed ID: 28709650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study.
    Okumura K; Lip GYH; Akao M; Tanizawa K; Fukuzawa M; Abe K; Akishita M; Yamashita T
    Am Heart J; 2017 Dec; 194():99-106. PubMed ID: 29223441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk impact of edoxaban in the management of stroke and venous thromboembolism.
    Hurst KV; O'Callaghan JM; Handa A
    Vasc Health Risk Manag; 2016; 12():329-35. PubMed ID: 27563246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial.
    Giugliano RP; Ruff CT; Wiviott SD; Nordio F; Murphy SA; Kappelhof JA; Shi M; Mercuri MF; Antman EM; Braunwald E
    Am J Med; 2016 Aug; 129(8):850-857.e2. PubMed ID: 26994510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials.
    Xiong Q; Lau YC; Senoo K; Lane DA; Hong K; Lip GY
    Eur J Heart Fail; 2015 Nov; 17(11):1192-200. PubMed ID: 26335355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct oral anticoagulants in atrial fibrillation.
    Noll G; Noll S; Hürlimann D
    Semin Hematol; 2014 Apr; 51(2):139-46. PubMed ID: 24861798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.